Promising Advancements and Strategic Collaborations Justify Buy Rating for Actinium Pharmaceuticals

Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) on May 13 and set a price target of $5.00.

Jason McCarthy has given his Buy rating due to a combination of factors that highlight Actinium Pharmaceuticals’ promising advancements in their radiopharmaceutical pipeline. The company is making significant progress in both liquid and solid tumor treatments, with pivotal trials in acute myeloid leukemia (AML) and solid tumors such as head and neck cancer and non-small cell lung cancer expected to yield initial data in the second half of 2025.
Actinium’s financial position is also noteworthy, as they reported a net loss that included a one-time non-cash charge, yet they maintain a cash runway extending to mid-2027. The company’s strategic collaborations, such as the Cooperative Research and Development Agreement with the National Cancer Institute, further bolster their research efforts. These developments, along with positive preclinical data for their ATNM-400 radiotherapy in prostate cancer, underscore the potential for Actinium’s therapies to address high unmet medical needs, justifying the Buy rating.

In another report released on May 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.